MEDIFAST INC Common Stock (MED)

Medifast (NYSEMED), the health and wellness company known for its habit based and coach-guided lifestyle solution OPTAVIA, today announced OPTAVIA ASCEND — a new product line of high-protein, fiber-rich mini meals as well as a daily nutrient pack. These products are featured in two new science-backed nutrition plans designed for people on GLP-1 medications and those looking for help to keep weight off. The mini meals provide essential nutrients to promote muscle health, digestive health and bone health, and combined with the new plans and OPTAVIA’s holistic offer, fill a critical gap in the weight management market.

Medifast (NYSEMED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessary.

Medifast (NYSEMED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024.

Medifast (NYSEMED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer.

Medifast (NYSEMED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024.

Medifast (NYSEMED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the second quarter ended June 30, 2024 on Monday, August 5, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer.

Medifast (NYSEMED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today announced that it has been recognized in the 2024-2025 rankings by U.S. News & World Report as one of the nation’s “Best Companies to Work For” in the food and drink industry. This recognition marks Medifast’s second straight year of inclusion on the list and underscores the company’s ongoing commitment to creating an outstanding workplace culture and enhancing the lives of its employees and customers.

LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result

Medifast (NYSEMED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today announced the launch of the first phase of its multimillion-dollar national marketing campaign. The campaign will highlight OPTAVIA’s new offering in collaboration with LifeMD®, the GLP-1 Lifestyle Program, a holistic approach to medical weight loss specifically tailored to support the needs of those utilizing GLP-1 medications. This robust offering, incorporating OPTAVIA’s lifestyle and personal coaching program, provides a comprehensive solution for individuals seeking a guided approach to weight management and who are committed to embarking on a life-changing health journey.

LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. (“Medifast” or “the Company”) (NYSEMED) for violations of the securities laws.

Medifast (NYSEMED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2024.

Medifast (NYSEMED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the first quarter ended March 31, 2024 on Monday, April 29, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer.

LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024

Medifast (NYSEMED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2023.

Medifast (NYSEMED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, February 20, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer.

Medifast (NYSEMED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today launched the first phase of its business transformation, as part of its commitment to providing comprehensive health and wellness solutions to customers across the United States. The company will expand into the medically supported weight loss market through a collaboration with LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care. This collaboration brings together OPTAVIA’s personalized habit-based, coach-guided approach with medical expertise from board-certified affiliated LifeMD clinicians and access to weight loss medications, including GLP-1s. This establishes Medifast’s entrance into the medically supported weight loss market, which is expected to reach up to $100 billion by 2030.*

Medifast (NYSEMED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2023.

Medifast (NYSEMED), the company behind the health and wellness community OPTAVIA®, will announce financial results for the third quarter ended September 30, 2023 on Monday, November 6, 2023, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer.

Institutions are buying undervalued consumer staples with solid cash flow, dividends, and healthy balance sheets like Medifast.

The consumer staples sector is beaten down and offering a significant value and high yield for long-term-minded investors

By Ernest Dela Aglanu, Benzinga

Palm Beach, FL – July 1, 2021 Astaxanthin may be the most important, potent supplements that most people don’t even know exists.  Astaxanthin is a powerful, naturally occurring carotenoid pigment that’s found in certain marine plants and animals. It is this that causes the pink or red color in salmon, lobster, trout and seafood. Often called “the king of the carotenoids,” Astaxanthin is recognized as being one of the most powerful antioxidants found in nature. Antioxidants are essential for helping combat free radical and oxidative damage to help support a healthy aging process and boost immunity. People take Astaxanthin because of its valuable antioxidant properties. Astaxanthin is 800x stronger than CoQ10, 6,000x stronger than Vitamin C, and 100x stronger than Vitamin E when it comes to antioxidant activity. Astaxanthin helps improve cellular function, and has been linked to improving healthy blood flow, hypertension, improved cardiovascular health, immune health, joint pain, eye health, cognitive alertness and muscle recovery from exercise. Moreover, it has been linked to helping smooth wrinkles, make age spots smaller, and maintain skin moisture.   A report from Market Research Future said that because Astaxanthin is said to have many health values it is projected that the Astaxanthin Market is expected to register a CAGR of 7.7% to reach USD 1,206.52 Million by 2026. “It’s been linked to heart health, endurance, healthier skin, joint pain and may even be applied in future cancer treatment. As a result of this, astaxanthin finds usages in more than a few industries, counting food and beverages, pharmaceuticals, animal feed, and nutraceuticals.”    Active companies in the markets this week include: Pressure BioSciences, Inc. (OTCQB: PBIO), Cyanotech Corporation (NASDAQCYAN), Perrigo Company plc NYSE: PRGONYSEPRGO)(NYSE: MEDNYSEMED, Archer-Daniels-Midland Company (NYSE: ADMNYSE).